Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Blackham A and Griffiths RJ | The effect of FK506 and cyclosporin A on antigen-induced arthritis. | 1991 | Clin. Exp. Immunol. | pmid:1718639 |
Carobbi A et al. | Effect of splenectomy in combination with FK 506 and 15-deoxyspergualin on cardiac xenograft survival. | 1991 | Transplant. Proc. | pmid:1703704 |
Fukuda T et al. | Inhibition of antigen-induced late asthmatic response and bronchial hyperresponsiveness by cyclosporin and FK 506. | 1991 | Int. Arch. Allergy Appl. Immunol. | pmid:1718889 |
Murase N et al. | FK 506 prevents spontaneous diabetes in the BB rat. | 1991 | Transplant. Proc. | pmid:1703705 |
Ericzon BG et al. | Pharmacokinetics of FK 506 during maintenance therapy in liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721273 |
Jain AB et al. | Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK 506. | 1991 | Transplant. Proc. | pmid:1721274 |
McMichael J et al. | Evaluation of a novel "intelligent" dosing system for optimizing FK 506 therapy. | 1991 | Transplant. Proc. | pmid:1721275 |
Ali Shah I et al. | Effects of FK 506 on human hepatic microsomal cytochrome P-450-dependent drug metabolism in vitro. | 1991 | Transplant. Proc. | pmid:1721276 |
Donnelly JG and Soldin SJ | Purification of a 50- to 58-kDa immunophilin from human spleen and a Jurkat T-cell line capable of binding cyclosporine A, FK 506, and rapamycin. | 1991 | Transplant. Proc. | pmid:1721305 |
Rosborough SL et al. | Identification of FKBP-related proteins with antibodies of predetermined specificity and isolation by FK 506 affinity chromatography. | 1991 | Transplant. Proc. | pmid:1721306 |
Zeevi A et al. | In vitro assessment of FK 506 immunosuppressive activity in transplant patients. | 1991 | Transplant. Proc. | pmid:1721307 |
Katz HR et al. | Mast cell biochemical and functional heterogeneity. | 1991 | Transplant. Proc. | pmid:1721308 |
Woodle ES et al. | FK 506: reversal of humorally mediated rejection following ABO-incompatible liver transplantation. | 1991 | Transplant. Proc. | pmid:1721337 |
Shaw BW et al. | FK 506 for rescue treatment of acute and chronic rejection in liver allograft recipients. | 1991 | Transplant. Proc. | pmid:1721338 |
McDiarmid SV et al. | FK 506 rescue therapy in liver transplantation: outcome and complications. | 1991 | Transplant. Proc. | pmid:1721339 |
Rucay P et al. | FK 506 rescue therapy for refractory acute rejection in five liver recipients. | 1991 | Transplant. Proc. | pmid:1721340 |
Macleod AM and Thomson AW | FK 506: an immunosuppressant for the 1990s? | 1991 | Lancet | pmid:1702172 |
Todo S et al. | Clinical small bowel or small bowel plus liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721369 |
Tzakis AG et al. | Use of FK 506 in pediatric patients. | 1991 | Transplant. Proc. | pmid:1703353 |
Fries D et al. | Development of renal dysfunction and renal histological lesions in two patients treated with FK 506 for acute rejection following liver transplantation. | 1991 | Transplant. Proc. | pmid:1721370 |
Jain AB et al. | Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1703354 |
Wijnen RM et al. | Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. | 1991 | Transplant. Proc. | pmid:1721371 |
Venkataramanan R et al. | Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1703355 |
Omar G et al. | FK 506 inhibition of cyclosporine metabolism by human liver microsomes. | 1991 | Transplant. Proc. | pmid:1703356 |
Lopez OL et al. | Neuropathologic findings in liver transplantation: a comparative study of cyclosporine and FK 506. | 1991 | Transplant. Proc. | pmid:1721400 |
Viebahn R et al. | Hypoxic and reoxygenation injury in human and rat hepatocytes--influence of FK 506 and cyclosporine. | 1991 | Transplant. Proc. | pmid:1721401 |
Morrisett JD et al. | Effect of FK 506 and cyclosporine on plasma cholesterol levels in rabbits. | 1991 | Transplant. Proc. | pmid:1721402 |
Jacobs TW et al. | The effect of FK 506, cyclosporine A, and cyclosporine G on serum 1,25-dihydroxyvitamin D levels. | 1991 | Transplant. Proc. | pmid:1721403 |
de Paulis A et al. | FK-506, a potent novel inhibitor of the release of proinflammatory mediators from human Fc epsilon RI+ cells. | 1991 | J. Immunol. | pmid:1706398 |
Griffiths EJ and Halestrap AP | Further evidence that cyclosporin A protects mitochondria from calcium overload by inhibiting a matrix peptidyl-prolyl cis-trans isomerase. Implications for the immunosuppressive and toxic effects of cyclosporin. | 1991 | Biochem. J. | pmid:1706598 |
Brabletz T et al. | The immunosuppressives FK 506 and cyclosporin A inhibit the generation of protein factors binding to the two purine boxes of the interleukin 2 enhancer. | 1991 | Nucleic Acids Res. | pmid:1707162 |
Valdivia LA et al. | Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721432 |
Wu GD et al. | FK 506 inhibits the development of transplant arteriosclerosis. | 1991 | Transplant. Proc. | pmid:1721433 |
Kobayashi N et al. | Effect of FK 506 on abdominal organ cluster transplantation in pigs. | 1991 | Transplant. Proc. | pmid:1721434 |
Wada H et al. | An attempt to induce tolerance to skin grafts in congenic mice with FK 506. | 1991 | Transplant. Proc. | pmid:1721435 |
Miyahara H et al. | Comparative studies of the effects of FK506 and cyclosporin A on passively transferred collagen-induced arthritis in rats. | 1991 | Clin. Immunol. Immunopathol. | pmid:1712688 |
McAlpine JB et al. | Revised NMR assignments for rapamycin. | 1991 | J. Antibiot. | pmid:1712766 |
Banerji SS et al. | The immunosuppressant FK-506 specifically inhibits mitogen-induced activation of the interleukin-2 promoter and the isolated enhancer elements NFIL-2A and NF-AT1. | 1991 | Mol. Cell. Biol. | pmid:1712901 |
Markus PM et al. | FK 506 reverses acute graft-versus-host disease after allogeneic bone marrow transplantation in rats. | 1991 | Surgery | pmid:1713358 |
McManus BM et al. | Impact of FK 506 on myocarditis in the enteroviral murine model. | 1991 | Transplant. Proc. | pmid:1721463 |
Nossal GJ | Summary of the First International FK 506 Congress: perspectives and prospects. | 1991 | Transplant. Proc. | pmid:1721464 |
Staruch MJ et al. | Differential effects of the immunosuppressive macrolides FK-506 and rapamycin on activation-induced T-cell apoptosis. | 1991 | Int. J. Immunopharmacol. | pmid:1721613 |
Matsuura T et al. | [Experimental studies on the mode of action of cyclosporine and FK506 assessed by proliferation response of human cloned T lymphocytes]. | 1991 | Hinyokika Kiyo | pmid:1721767 |
Morris PJ | Cyclosporine, FK-506 and other drugs in organ transplantation. | 1991 | Curr. Opin. Immunol. | pmid:1721824 |
Pourtier-Manzanedo A et al. | FK-506 (fujimycin) reverses the multidrug resistance of tumor cells in vitro. | 1991 | Anticancer Drugs | pmid:1724925 |
Nakahama H et al. | Comparative effects of cyclosporine A and FK-506 on endothelin secretion by a cultured renal cell line, LLC-PK1. | 1991 | J. Cardiovasc. Pharmacol. | pmid:1725322 |
Romanowski P et al. | [Synthetic immunomodulators designed on the basis of natural products of microorganisms]. | 1991 | Postepy Biochem. | pmid:1725924 |
James DG | Which immunomodulator? | 1991 | Br J Clin Pract | pmid:1718384 |
Flavin T et al. | Initial experience with FK 506 as an immunosuppressant for nonhuman primate recipients of cardiac allografts. | 1991 | Transplant. Proc. | pmid:1703701 |
Jiang H et al. | Effect of FK 506 on heart allograft survival in highly sensitized recipient rats in comparison with cyclosporine. | 1991 | Transplant. Proc. | pmid:1703702 |